NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD
596.2
+8.61 (+1.47%)
The current stock price of ARGX is 596.2 USD. In the past month the price decreased by -2.75%. In the past year, price increased by 65.51%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B | ||
INSM | INSMED INC | N/A | 13.21B |
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1148
Company Website: https://www.argenx.com/
Investor Relations: https://www.argenx.com/investors
Phone: 31763030
The current stock price of ARGX is 596.2 USD. The price increased by 1.47% in the last trading session.
The exchange symbol of ARGENX SE - ADR is ARGX and it is listed on the Nasdaq exchange.
ARGX stock is listed on the Nasdaq exchange.
25 analysts have analysed ARGX and the average price target is 772.09 USD. This implies a price increase of 29.5% is expected in the next year compared to the current price of 596.2. Check the ARGENX SE - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARGENX SE - ADR (ARGX) has a market capitalization of 36.23B USD. This makes ARGX a Large Cap stock.
ARGENX SE - ADR (ARGX) currently has 1148 employees.
ARGENX SE - ADR (ARGX) has a support level at 555.1 and a resistance level at 602.18. Check the full technical report for a detailed analysis of ARGX support and resistance levels.
The Revenue of ARGENX SE - ADR (ARGX) is expected to grow by 60.95% in the next year. Check the estimates tab for more information on the ARGX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARGX does not pay a dividend.
ARGENX SE - ADR (ARGX) will report earnings on 2025-05-08, before the market open.
The PE ratio for ARGENX SE - ADR (ARGX) is 318.82. This is based on the reported non-GAAP earnings per share of 1.87 and the current share price of 596.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.
The outstanding short interest for ARGENX SE - ADR (ARGX) is 3.29% of its float. Check the ownership tab for more information on the ARGX short interest.
ChartMill assigns a technical rating of 5 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 94.24% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ARGX. The financial health of ARGX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 1.87. The EPS increased by 133.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 38.03% | ||
ROA | 17.37% | ||
ROE | 19.54% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 84% to ARGX. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 581.8% and a revenue growth 60.95% for ARGX